Please Find Enclosed Herewith Outcome of the Board Meeting For year ended 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Bio Systems Limited reported its audited results for FY25 with total income of Rs. 19.25 lakhs (vs nil in FY24) from a fresh revenue stream. However, total expenses surged to Rs. 73.98 lakhs (vs Rs. 14.07 lakhs), leading to a loss before tax of Rs. 54.73 lakhs, nearly four times wider than the Rs. 14.07 lakh loss in FY24. Loss per share widened to Rs. 0.78 from Rs. 0.20. The company also burnt Rs. 458.46 lakhs in operating cash flow and ended the year with negative reserves of Rs. 109.77 lakhs, even as borrowings jumped sharply. The statutory auditor issued an unmodified opinion.
The wider losses, negative reserves, and heavy cash burn signal continued financial stress and dependence on borrowings, which is negative for shareholders. Despite a clean audit opinion, the deteriorating fundamentals and the need for fresh debt of Rs. 457 lakhs to fund operations raise concerns about the company's ability to sustain itself without further capital infusion.